Effects of NPC16377, a potent and selective sigma receptor ligand, on the activity of mesencephalic dopamine-containing neurons in the rat.

NPC16377 is a highly selective sigma receptor ligand with low affinity for other neurotransmitter receptors. Preclinical studies indicate that the drug exhibits a pharmacological profile similar to that previously ascribed to atypical antipsychotic drugs. In the present series of experiments, extracellular recording techniques were used to assess the acute effects of NPC16377 on the electrophysiological properties of mesencephalic dopamine-containing neurons in the rat. Systemic administration of NPC16377 produced marginal increases in the firing rate of these neurons but failed to fully reverse the inhibitory effects of the dopamine agonists apomorphine and d-amphetamine. Low doses of the drug potentiated the rate-decreasing effects of d-amphetamine in the substantia nigra but not in the ventral tegmental area. Some of these effects are similar to the actions of atypical antipsychotic drugs, while others appear to be unique to this compound and may involve a direct interaction with sigma sites.

[1]  W. Bowen,et al.  Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study , 1992, Brain Research.

[2]  A. Halaris,et al.  Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics , 1985 .

[3]  S J Young,et al.  Self-inhibition by dopaminergic neurons , 1975, Science.

[4]  S. Iversen,et al.  Behavioral implications of dopaminergic neurons in the mesolimbic system. , 1977, Advances in biochemical psychopharmacology.

[5]  G. F. Steinfels,et al.  Electrophysiological effects of selective sigma-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[6]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[7]  F. J. White,et al.  Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. , 1988, The Journal of pharmacology and experimental therapeutics.

[8]  M. Pontecorvo,et al.  Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. , 1993, The Journal of pharmacology and experimental therapeutics.

[9]  B. Bunney,et al.  The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. , 1984, European journal of pharmacology.

[10]  S. Iversen,et al.  Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum , 1975, Brain Research.

[11]  C. W. Ragsdale,et al.  Fibers from the basolateral nucleus of the amygdala selectively innervate striosomes in the caudate nucleus of the cat , 1988, The Journal of comparative neurology.

[12]  Duncan P. Taylor,et al.  Potential antipsychotic BMY 14802 selectively binds to sigma sites , 1987 .

[13]  H. Wikström,et al.  Sigma-receptors: implication for the control of neuronal activity of nigral dopamine-containing neurons. , 1991, European journal of pharmacology.

[14]  Y. Itzhak,et al.  Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. , 1990, Life sciences.

[15]  A. Ceci,et al.  Activation of the A10 mesolimbic system by the sigma-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic. , 1988, European journal of pharmacology.

[16]  Stein Gf,et al.  Selective σ receptor agonist and antagonist affect dopamine neuronal activity , 1989 .

[17]  L. Chiodo,et al.  Repeated administration of Sigma ligands alters the population activity of rat midbrain dopaminergic neurons , 1993, Synapse.

[18]  J. Piontek,et al.  Acute and subchronic effects of Rimcazole (BW 234U), a potential antipsychotic drug, on A9 and A10 dopamine neurons in the rat. , 1986, Life sciences.

[19]  R. Matthews,et al.  Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function. , 1986, The Journal of pharmacology and experimental therapeutics.

[20]  A. Graybiel,et al.  Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[21]  A. Grace,et al.  Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. , 1979, Science.

[22]  B. Bunney The effect of antipsychotic drugs on the firing of dopaminergic neurons. A reappraisal , 1974 .

[23]  Rex Y. Wang Dopaminergic neurons in the rat ventral tegmental area. III. Effects of d-and l-amphetamine , 1981, Brain Research Reviews.

[24]  R. Faull,et al.  Autoradiographic distribution of sigma receptors in human neocortex, hippocampus, basal ganglia, cerebellum, pineal and pituitary glands , 1991, Brain Research.

[25]  C. W. Ragsdale,et al.  The fronto-striatal projection in the cat and monkey and its relationship to inhomogeneities established by acetylcholinesterase histochemistry , 1981, Brain Research.

[26]  T. Su Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. , 1982, The Journal of pharmacology and experimental therapeutics.

[27]  M. Pontecorvo,et al.  NPC 16377, a potent and selective sigma-ligand. I. Receptor binding, neurochemical and neuroendocrine profile. , 1993, The Journal of pharmacology and experimental therapeutics.

[28]  D. Mash,et al.  Sigma receptors are associated with cortical limbic areas in the primate brain , 1992, Synapse.

[29]  R. Roth,et al.  Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. , 1973, The Journal of pharmacology and experimental therapeutics.

[30]  W. Zeman The Rat Drain. A Stereotaxic Atlas , 1964 .

[31]  A. Grace,et al.  Nigral dopamine neurons: intracellular recording and identification with L-dopa injection and histofluorescence. , 1980, Science.

[32]  A. Ceci,et al.  Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons , 1990, Neuroscience Letters.

[33]  L. Chiodo,et al.  Acute effects of Sigma ligands on the electrophysiological activity of rat nigrostriatal and mesoaccumbal dopaminergic neurons , 1992, Synapse.

[34]  G. Debonnel Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. , 1993, Journal of psychiatry & neuroscience : JPN.

[35]  S. Snyder,et al.  Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. , 1989, The Journal of neuropsychiatry and clinical neurosciences.

[36]  J. Walters,et al.  Action of systemic apomorphine on dopamine cell firing after neostriatal kainic acid lesion , 1980, Brain Research.

[37]  M. Pontecorvo,et al.  NPC 16377, a potent and selective sigma-ligand. II. Behavioral and neuroprotective profile. , 1993, The Journal of pharmacology and experimental therapeutics.

[38]  J. Hedreen,et al.  Sigma receptors in post-mortem human brains. , 1988, The Journal of pharmacology and experimental therapeutics.

[39]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[40]  S. Snyder,et al.  Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. , 1986, The Journal of pharmacology and experimental therapeutics.

[41]  H. Ujike,et al.  Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization. , 1992, Life sciences.

[42]  M. H. Aprison Advances in biochemical psychopharmacology: Volume 1, edited by E. Costa and P. Greengard, Raven press (1969) , 1970 .